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Activation of K-ras oncogene has been implicated in colo-
rectal carcinogenesis, being mutated in 30±60% of the
adenocarcinomas. In this study, 737 incident colorectal
cancer (CRC) patients, originating from 120 852 men and
women (55±69 years at baseline) participating in the
Netherlands Cohort Study (NLCS), were studied in order
to evaluate subgroups with respect to K-ras mutation
status. Mutation analysis of the exon 1 fragment of the
K-ras oncogene, spanning codons 8±29, was performed on
archival colorectal adenocarcinoma samples of all patients
using macrodissection, nested PCR and direct sequencing
of purified fragments. The method of mutation detection
was validated by the confirmation of reported K-ras status
in CRC cell lines, a good correlation between fresh-frozen
and routinely fixed, paraffin-embedded tissue, a detection
limit of 5% mutated DNA and a good reproducibility.
Various types of K-ras mutations were evaluated with
respect to tumour sub-localization, Dukes' stage and
tumour differentiation. In 37% (271/737) of the patients,
the exon 1 fragment of K-ras gene was found to be mutated.
The predominant mutations are G>A transitions and G>T
transversions, and codons 12 and 13 are the most fre-
quently affected codons. Patients with a rectal tumour
were found to have the highest frequency of G>T transver-
sions as compared with patients with a colon or rectosig-
moid tumour. This difference appeared to be confined to
women with a rectal tumour harbouring G>T transver-
sions. No significant differences were observed for Dukes'
stage with respect to types of K-ras mutation, which does
not support direct involvement of the K-ras oncogene in
adenocarcinoma progression. The equal distribution of
K-ras mutations among cases with or without a family
history of colorectal cancer argues against an important
role for this mutation in familial colorectal cancer,
and could imply that K-ras mutations are more probably
involved in environmental mechanisms of colorectal
carcinogenesis.
Introduction
The development of colorectal cancer (CRC) is a multi-step
process characterized by the accumulation of genetic alterations
(1,2). The Fearon and Vogelstein model assumes the involve-
ment of the APC (Adenomatous Polyposis Coli) gene in ade-
noma formation and the K-ras oncogene in the transition from
intermediate adenomas to carcinomas in sporadic CRC (1).
The K-ras oncogene has been found mutated in 10±15% of
the screened adenomas<1 cm and in 30±60% of adenomas>1
cm. Also, 30±60% of the adenocarcinomas have a K-ras muta-
tion (3±5). It was suggested, therefore, that a mutated
K-ras gene contributes to the transition of an intermediate
adenoma to a late adenoma or carcinoma (2). The K-ras gene
product, a 21 kDa protein located at the inner plasma mem-
brane, is involved in the transduction of mitogenic signals.
The Ras protein is activated transiently as a response to extra-
cellular signals such as growth factors, cytokines and hor-
mones that stimulate cell surface receptors (6). The hallmark
of Ras function is a switch between an inactive state, in which
the proteins are bound to guanosine-diphosphates (GDP) and
an active state in which conversion to guanosine-triphosphates
(GTP) has occurred. This transit is governed by two types of
regulatory proteins: GDP±GTP exchange factors that catalyse
the GDP±GTP exchange and GTPase-activating proteins that
enhance the intrinsic capacity of Ras proteins to hydrolyse
GTP into GDP, thereby returning Ras to the inactive state (7).
Mutant, activated forms of Ras proteins have an impaired
intrinsic GTPase activity, which renders the protein resistant to
inactivation by regulatory GTPase-activating proteins (4).
Approximately 90% of the activating mutations are found in
codons 12 (wild-type GGT) and 13 (wild-type GGC) of exon 1
and ~5% in codon 61 (wild-type CAA) located in exon 2
(8±10). Previous studies from various countries have revealed
specific point mutations in codons 12 and 13. The most fre-
quently observed types of mutations are G>A transitions (11)
and G>T transversions (12) and these alterations were found
associated with gender and sub-localization of the tumour (9).
To date, frequencies and specific types of point mutations in
the K-ras oncogene in colorectal cancer have been investigated
in several studies (4,5,10,13). These reports were generally
based on small numbers of selected patients. In the current
study, however, the frequency of K-ras mutations is studied in
a large series of unselected, incident colorectal cancer patients
from The Netherlands identified in a prospective cohort study.
Potential differences in tumour sub-localization, Dukes' stage
and tumour differentiation with respect to presence and type of
the K-ras mutations are studied.
Materials and methods
Study population
The participants in this study are incident colorectal cancer cases from the
Netherlands Cohort Study (NLCS) on diet and cancer. The NLCS has been
Abbreviations: CRC, colorectal cancer; GDP, guanosine-diphosphates; GTP,
guanosine-triphosphates; NLCS, Netherlands Cohort Study.
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described in detail elsewhere (14). Briefly, the prospective study was initiated
in 1986 and includes 58 279 men and 62 573 women, aged between 55 and
69 years old, who completed a self-administered questionnaire on diet, family
history of cancer and other risk factors for cancer at baseline. The entire cohort
is being monitored for cancer occurrence by annual record linkage to the
Netherlands Cancer Registry (NCR) and to PALGA, a nationwide database
of pathology reports (15). From 1989 until 1994, with exclusion of the first 2.3
years of follow up due to incomplete nationwide coverage of PALGA, 819
incident cases with histologically confirmed colorectal cancer have been
identified. The PALGA database was also used to identify the location of
tumour tissue storage in the Dutch PA laboratories. Colorectal cancer was
classified according to site as follows. Proximal colon: cecum through trans-
verse colon (ICD-O codes: 153.0, 153.1, 153.4, 153.5, 153.6); distal colon:
splenic flexure through sigmoid colon (ICD-O codes: 153.2, 153.3, 153.7);
rectosigmoid (ICD-O code 154.0) and rectum (ICD-O code 154.1). Informa-
tion about age at diagnosis, gender and family history of colorectal cancer
(at baseline) was retrieved from the NLCS database. Information about tumour
sub-localization, Dukes' stage and differentiation of the tumour was retrieved
from the Netherlands Cancer Registry database.
Tissue samples
Tumour material was collected after approval by the Medical Ethical Commit-
tees (MEC) of the Maastricht University, PALGA and the NCR. Subsequently,
all pathology laboratories in the Netherlands agreed to make relevant tissue
samples available for this study. Tumour tissue sample collection started in
August, 1999 and was completed in December, 2001. The 819 tissue samples
were distributed among 54 pathology laboratories throughout The Netherlands,
and only 44 (5%) tumour tissue samples could not be traced. Finally, 775
(95%) of the eligible tissue samples have been retrieved and 737 (90%) of the
tissue samples contained sufficient tumour material as confirmed by a path-
ologist (A.d.B.) and hence were available for molecular analyses. Archival
tissue sample blocks were registered and coded using a consecutive, unique
identification number.
Five CRC cell lines, i.e. HT29, Colo205, CaCo2, SW480 and HCT116
[American Type Culture Collection (ATCC), Rockville, MD] were used to
check the specificity of K-ras mutation detection. In order to validate mutation
analysis on paraffin-embedded tissue, 10 fresh CRC specimens were divided
into two adjacent tissue blocks, one of which was fresh-frozen, and one
routinely fixed and embedded in paraffin. These specimens were obtained
from patients who did not participate in the NLCS.
DNA isolations
Sections (5 mm) were cut from paraffin-embedded tumour tissue blocks and
stained with haematoxylin & eosin (H&E) for histopathological examination.
For DNA isolation, five 20 mm sections of tumour tissue were used. Deparaf-
fination of the sections was performed and, using the H&E section as a
reference, tumour tissue was macrodissected from the normal colonic epithe-
lium and scraped off.
Genomic DNA was extracted from macrodissected tumour tissue using the
Puregene1 DNA isolation kit (Gentra Systems). Briefly, 475 ml cell lysis
solution and 25 ml proteinase K stock solution (20 mg/ml, obtained from
Qiagen, St Louis, MO) were added to the tissue samples and incubated over-
night at 55C. Subsequently, DNA was extracted for 72 h at 37C, protein was
removed and DNA was precipitated using 100% 2-propanol and dissolved in
hydration buffer. The DNA concentration and purity was measured at 260 and
280 nm.
DNA from fresh, unfixed CRC cell lines and the fresh-frozen tissue samples
was extracted as described for paraffin-embedded sections.
Mutation analysis
An exon 1 fragment of the K-ras gene was amplified from isolated, genomic
DNA using a nested PCR approach. In the first reaction, a fragment of 179 bp
was generated, using the sense primer 50-AGG CCT GCT GAA AAT GAC
TGA ATA-30 and antisense primer 50-CTG TAT CAA AGA ATG GTC CTG
CAC-30. The annealing temperature was 58C. The resulting fragment was
used as a template to amplify a 114 bp fragment spanning codons 8±29. This
PCR is performed using the biotinylated, sense primer 50-AAA ATG ACT
GAA TAT AAA CTT GTG G-30 and the antisense primer 50-CTC TAT TGT
TGG ATC ATA TTC GTC-30 at an annealing temperature of 50C. The inside
products were checked for purity and size by electrophoresis on a 2% agarose
gel and subsequently used for direct sequencing.
Mutations in the exon 1 fragment of the K-ras gene were detected by direct
sequencing with a solid phase sequencing kit (Amersham Pharmacia) using the
ALFexpress II DNA sequencer (Pharmacia Biotech). In brief, the biotinylated
PCR product is captured on a sequencing comb coated with streptavidin.
After removal of the non-biotinylated strands by alkaline denaturation, the
remaining immobilized strand was used as a template for dideoxy sequencing
reactions with a Cy5 labelled primer 50-CTC TAT TGT TGG ATC ATA TTC
GTC CAC-30 and T7 DNA polymerase. The sequence profile is analysed on
the ALFexpress II DNA Analysis System. Evaluation was independently
performed using ALFwin software (Amersham Pharmacia Biotech) by two
observers, based on the criterion that an increase of at least 5% is observed for
the mutant peak as well as a decrease of at least 5% in the wild-type peak,
relative to the wild-type pattern in the same sequence run. Data entry was
performed blindly by two independent observers.
The mutation detection limit was determined by mixing wild-type DNA
from the cell line CaCo2 and the homozygously mutated cell line SW480 in
amounts varying from 0±100%.
Statistical analysis
The overall frequency of K-ras mutations as well as the type of mutation and
affected codon was computed for all 737 cases with respect to age at diagnosis,
gender, family history of colorectal cancer, tumour sub-localization, Dukes'
stage and tumour differentiation. Differences in mean values of age at
diagnosis as a continuous variable was evaluated using the Student's t-test.
Differences in the categorical variables gender, family history of colorectal
cancer, tumour sub-localization, Dukes' stage and tumour differentiation
between patients without and with K-ras mutations were evaluated for sig-
nificance with the w2-test. In addition, differences in tumour sub-localization,
Dukes' stage and tumour differentiation between patients without a K-ras
mutation and patients with one or more G>A transition or G>T transversion
or patients with at least one codon 12 or codon 13 mutation were evaluated
with the w2-test. A P-value of 0.05 or less was considered statistically
significant. Statistical analyses were performed using the SPSS software
(version 9.0).
Results
Validation of techniques
In the colorectal cancer cell lines HT29, Colo205 and CaCo2,
wild-type K-ras was found, whereas homozygously mutated
alleles in SW480 and heterozygously mutated alleles in
HCT116 cells were revealed with direct sequence analysis.
For the SW480 line, a GGT to GTT mutation in codon 12
was observed and for the HCT116 line, a GGC to GAC muta-
tion in codon 13.
The effect of tissue processing was assessed by comparing
an adjacent fresh-frozen and a paraffin-embedded tissue block
in a series of 10 fresh colon tumour specimens. In nine speci-
mens, the K-ras status in the paraffin-embedded tissue was
identical to fresh, unfixed tissue, i.e. six specimens with wild-
type K-ras, one with a G>T transversion at the second position
of codon 12, one with a G>C transversion at the second
position of codon 12 and one with a G>C transversion at the
second position of codon 13. In one specimen, a G>C trans-
version at the third position of codon 19 was observed in the
routinely fixed, paraffin-embedded tissue, but not in DNA
extracted from the fresh tissue.
The detection limit of mutation detection was determined by
mixing wild-type DNA isolated from the CaCo2 cell line with
decreasing concentrations of mutated DNA which was pre-
pared from the homozygously mutated colorectal cell line
SW480. The lowest level of detection was 5% mutant DNA
in a background of wild-type DNA as found in three indepen-
dent experiments.
To establish the reproducibility of the mutation analysis,
32 NLCS adenocarcinoma specimens were subjected twice to
the complete procedure, from tissue sectioning to DNA
sequencing. In 88% (28/32) of the samples, the same K-ras
status was observed in the duplicate experiments.
Types of mutations
In exon 1 of the K-ras oncogene, a total of 281 mutations were
found in 271 (37%) out of 737 patients. No significant differ-
ences were observed in mean age at diagnosis (67.75  4.21
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versus 68.29  4.32), gender (55 versus 57%) and family
history of colorectal cancer (11 versus 9%) between patients
without and patients with one or more K-ras oncogene muta-
tions in the tumour (Table I).
For 10 patients, two different mutations were observed in
exon 1. In six of these patients both mutations were found
in codon 12, and the other four patients showed one mutation
in codon 12 or codon 13 and one mutation in another codon. In
18 patients without aberrations in codon 12 or codon 13, a
mutation was found in codons 8, 9, 10, 15, 16, 19, 20 or 25.
Table II summarizes the frequencies of genetic aberrations
by type of mutation, affected codons and corresponding amino
acids in the exon 1 fragment of the K-ras oncogene. The most
frequently observed mutations in the gene are G>A transi-
tions, G>T transversions and G>C transversions, i.e. 55 (155/
281 mutations), 32 (90/281 mutations) and 9% (24/281 muta-
tions), respectively. Of the total number of mutations in the
exon 1 fragment, 72% (201/281) was observed in codon 12
(GGT) and 22% (62/281) in codon 13 (GGC). In codon 12, the
GAT codon (37%) leading to aspartic acid and the GTT codon
(35%) leading to valine were the most frequently observed
(Table 2). In codon 13 the G>A transition at the second base,
which would lead to substitution of a glycine by aspartic acid,
was by far the predominant mutation (94%). Furthermore, the
point mutations (17/277) observed in codons 8, 10, 15, 16, 19,
20 and 25 were all transitions. In one case, an insertion of six
nucleotides was observed in codon 9, leading to one altered
codon and two inserted codons, however, without a frameshift
in the gene (Table II). The only alteration in the protein is the
insertion of two extra amino acids.
Tumour sub-localization
Patients with rectal tumours have relatively the highest fre-
quency of K-ras mutations as compared with patients with
proximal or distal colon tumours or patients with a rectosig-
moid tumour (42 versus 38%, 30 and 40%, respectively, P 
0.09) (Table III). Moreover, different tumour sub-localizations
showed different frequencies of G>T transversions as well as
different frequencies of codon 12 or codon 13 mutations.
Patients with a rectal tumour have the highest frequency of
G>T transversions (16 versus 11%, 9 and 14% for proximal,
distal and rectosigmoid tumours, respectively, P  0.22) and
codon 12 mutations (34 versus 25%, 22 and 25%, respectively,
P  0.07) (Table III). It should be noted that most G>T
transversions are confined to codon 12 (Table II). Patients
with a tumour in the rectosigmoid, however, have the highest
frequency of codon 13 mutations (14 versus 11%, 5 and 6% for
proximal, distal and rectal tumour, respectively, P  0.03)
(Table III). Stratification by gender, in addition, reveals that
women with a rectal tumour have the highest prevalence of
K-ras mutations (53 versus 37%, 23 and 37% for proximal,
distal and rectosigmoid tumour, respectively, P  0.001). This
difference was confined, in particular, to the G>T transver-
sions (27% for rectal tumour versus 8%, 11 and 7% for
Table I. Characteristics of CRC cases (n  737) subdivided into cases without a K-ras (n  466) mutation and cases with at least one K-ras mutation (n  271)
Total cases (n  737) Cases with wild-type K-ras (n  466) Cases with K-ras mutation (n  271) P-valuea
Age at diagnosis (mean  SD) 67.95  4.26 67.75  4.21 68.29  4.32 0.10
Gender (men) 410 (56%) 257 (55%) 153 (57%) 0.73
Family history of CRC (yes) 76 (10%) 53 (11%) 23 (9%) 0.21
aComparing cases with at least one K-ras mutation to cases without a K-ras mutation.
Table II. Number and type of mutations, affected codons and corresponding altered amino acids in exon 1 of the K-ras gene
Codona Type of point
mutationa
Number of point
mutations
Wild-type codona
(amino acidb)
Mutated codona
(amino acidb)
Putative altered
amino acid
8 A>G 3 (1%) GTA (val) GTG (val) 3
9 Insertionc 1 (0.4%) GTT (val) GTG (val)-GAG (glz)-CTT (leu) 1
10 G>A 1 (0.4%) GGA (gly) AGA (arg) 1
12 G>A 91 (33%) GGT (gly) GAT (asp) 75 (37%)
AGT (ser) 16 (8%)
G>T 87 (31%) GTT (val) 70 (35%)
TGT (cys) 17 (8%)
G>C 23 (8%) GCT (ala) 16 (8%)
CGT (arg) 7 (3%)
13 G>A 58 (21%) GGC (gly) GAC (asp) 58 (94%)
G>T 3 (1%) TGC (arg) 3 (5%)
G>C 1 (0.4%) CGC (cys) 1 (2%)
15 G>A 1 (0.4%) GGC (gly) AGC (ser) 1
16 G>A 1 (0.4%) AAG (lys) AAA (lys) 1
19 G>A 1 (0.4%) TTG (leu) TTA (leu) 1
20 C>T 8 (3%) ACG (thr) ATG (met) 8
25 G>A 2 (0.8%) CAG (glu) CAA (glu) 2
aFor 10 patients, two mutations were found and these are included in this table.
bgly, glycine; asp, aspartic acid; ser, serine; val, valine; cys, cysteine; ala, alanine; arg, arginine; thr, threonine; met, methionine; glu, glutamine; leu, leucine;
glz, glutamic acid.
cThe insertion is six nucleotides (TGGAGC), located after the first position of codon 9, resulting in three altered codons.
K-ras mutation in The Netherlands Cohort Study
705
proximal and distal colon tumour and rectosigmoid tumour,
respectively, P  0.002) (Table IV). We also evaluated
the K-ras mutational status for tumours in the proximal and
distal colon and for tumours in the colon versus the rectum
(tumours in the rectosigmoid were excluded for this analysis).
It was found that patients with a proximal colon tumour had a
higher frequency of G>A transitions as compared with
patients with a distal tumour (P  0.11) (Table III). This
difference in frequencies of G>A transitions with respect
to proximal and distal colon tumours was more pronounced
for women (P 0.02) (Table IV). Patients with a rectal tumour
showed a relatively higher frequency of K-ras mutations
(P  0.08), and in particular G>T transversions (P  0.06),
as compared with patients with a colon tumour. Again, this
difference was due to the high frequency of G>T transver-
sions in rectal tumours observed in women (P  0.0003)
(Table IV).
Dukes' stage
Most tumours were staged as Dukes B (35%, 238/685),
and tumours with Dukes D stage (12%, 85/685) constitute
the smallest group (Table III). Patients with a Dukes A
staged tumour more often have G>A transitions (26 versus
16, 20 and 19% for Dukes B, C and D, respectively; P 0.13),
whereas patients with a Dukes D staged tumour have relatively
a higher frequency of G>T transversions (18 versus 8, 15 and
9% for Dukes A, B and C, respectively; P  0.04). No clear
differences were observed in the frequencies of codon 12 or
Table III. Characterization of K-ras mutations at gene and codon level according to tumour sub-localization, Dukes' stage and differentiation of the tumour
Total CRC
cases
(n  737)d
Wild-type
K-ras
/it> (n  466)
K-ras
mutation
(n  271)d
Point mutation Affected codon
G>A transition
(n  153)d;e
G>T transversion
(n  88)d;e
G>C transversion
(n  23)d;e
Codon 12
(n  195)d;e
Codon 13
(n  62)d;e
Sub-localizationa
Proximal colon 240 149 (62%) 91 (38%) 55 (23%) 27 (11%) 7 (3%) 61 (25%) 26 (11%)
Distal colon 224 156 (70%) 68 (30%) 38 (17%) 20 (9%) 6 (3%) 50 (22%) 12 (5%)
Rectosigmoid 85 51 (60%) 34 (40%) 20 (24%) 12 (14%) 2 (2%) 21 (25%) 12 (14%)
Rectum 176 102 (58%) 74 (42%) 37 (21%) 28 (16%) 9 (5%) 60 (34%) 11 (6%)
P-valueb 0.09 0.39 0.22 0.48 0.07 0.03
Dukes' stagec
A 179 114 (64%) 65 (36%) 46 (26%) 15 (8%) 2 (1%) 46 (26%) 17 (9%)
B 238 154 (65%) 84 (35%) 39 (16%) 36 (15%) 7 (3%) 61 (26%) 18 (8%)
C 183 120 (66%) 63 (34%) 37 (20%) 17 (9%) 9 (5%) 43 (23%) 17 (9%)
D 85 47 (55%) 38 (45%) 16 (19%) 15 (18%) 4 (5%) 26 (31%) 8 (9%)
P-valueb 0.40 0.13 0.04 0.17 0.68 0.88
aFor eight patients without a K-ras mutation and four patients with at least one mutation, the site of localization in the colon could not be determined (colon, NOS).
bComparing patients without a K-ras mutation to patients with at least one K-ras mutation, patients with at least one G>A transition (n  153) or those with at
least one G>T (n  88) or G>C (n  23) transversion.
cFor 21 patients without a K-ras mutation and 31 patients with at least one K-ras mutation, information on Dukes' stage was not available.
dFor 10 patients, two mutations were found. These patients were included in the analyses and treated as patients with at least one K-ras mutation, etc.
eThe frequencies of G>A transition, G>T or G>C transversion per subsite were calculated by dividing the number of patients with G>A transitions,
for example, through the total number of CRC cases.
Table IV. Stratification by gender with respect to tumour sub-localization
No K-ras mutation K-ras mutationc G>A transitionc G>T transversionc G>C transversionc
Men
Sub-localizationa 252 151 87 47 11
Proximal colon 71 (61%) 45 (39%) 25 (22%) 17 (15%) 0 (0%)
Distal colon 84 (64%) 47 (36%) 27 (21%) 10 (8%) 6 (5%)
Rectosigmoid 25 (57%) 19 (43%) 9 (20%) 9 (21%) 1 (2%)
Rectum 72 (64%) 40 (36%) 24 (21%) 11 (9%) 5 (4%)
P-valueb 0.77 0.99 0.07 0.13
Women
Sub-localizationa 206 116 66 40 12
Proximal colon 78 (63%) 46 (37%) 30 (24%) 10 (8%) 7 (6%)
Distal colon 72 (77%) 21 (23%) 11 (12%) 10 (11%) 0 (0%)
Rectosigmoid 26 (63%) 15 (37%) 11 (27%) 3 (7%) 1 (2%)
Rectum 30 (47%) 34 (53%) 13 (20%) 17 (27%) 4 (6%)
P-valueb 0.001 0.09 0.002 0.10
aFor five male patients and three female patients without a K-ras mutation and two male patients and two female patients with at least one mutation, the site of
localization in the colon could not be determined (colon, NOS)
bComparisons between patients without a K-ras mutation and patients with at least one K-ras mutation, patients with at least one G>A transition, G>T or
G>C transversion.
cThe frequencies of G>A transition, G>T or G>C transversion per sub-localization and gender was calculated by dividing the number of patients with G>A
transitions, for example, through the total number of CRC patients.
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codon 13 mutations with respect to the Dukes' stage of the
tumour (Table III).
Tumour differentiation
No differences were observed in frequencies of K-ras muta-
tions, G>A transitions, G>T or G>C transversions or
mutations in codon 12 or codon 13 (P > 0.05) with respect
to tumour differentiation.
Discussion
Overall, we observed that the frequency of K-ras oncogene
mutations in a large representative sample of CRC patients
from The Netherlands (age at diagnosis between 57 and 76
years) was 37%. The frequency of K-ras gene mutations in
CRC patients reported in the literature, ranges from 30 to 60%
(3,9,11,12,16±27). This broad range of reported frequencies of
K-ras mutations may be due to various factors, such as the
sensitivity and specificity of mutation detection methods,
small series of selected patients (3,12,17,20,21,23) and/or
variability in analysed gene region, i.e. only codons 12 (21),
13 (12,20,22,23,28) and/or 61 (11). Also, environmental factors
may be involved. Techniques used for mutation screening such
as temperature gradient gel electrophoresis (3) or SSCP (17,29)
and methods for mutation detection like PCR-restriction frag-
ment length polymorphism (22,28), or PCR-based mutant
allele-specific amplification (MASA) (20) may show differ-
ences in sensitivity and/or specificity of mutation detection in
the K-ras gene. In this study, the analysis of K-ras mutations
is based on a highly sensitive and specific detection method,
i.e. direct sequencing of purified PCR fragments. This method
identifies mutations in DNA samples, which contain at least 5%
or more mutated DNA. The reported frequency of K-ras muta-
tions could, therefore, be an underestimation. Direct sequencing
was validated by mutation analysis of five CRC cell lines, and
of adjacent blocks with paraffin-embedded and fresh tissue
from a series of 10 CRC specimens. The mutation analysis of
five CRC cell lines confirmed the reported sequences of exon 1
fragments of the K-ras oncogene (30). In addition, the K-ras
status as determined in paraffin-embedded tumour tissue
was also found in fresh tumour tissue in nine out of
10 specimens. In one specimen, the mutation detected in
paraffin-embedded tissue was not found in fresh tissue, which
may be related to heterogeneity in the tumour tissue or a lack in
the reproducibility of this sample. These results indicate that
tissue processing does not significantly affect the reliability of
mutation analysis in archival specimens. The reproducibility
of the identification technique used in this study was found
to be good, as duplication of the complete analytical
procedure yielded the same results for 28 out of 32 (88%)
adenocarcinomas. The K-ras gene mutation analysis is
based on a relatively large series of non-selected, incident
CRC patients, which indicates that the found frequency of
K-ras mutations is representative for colorectal cancer patients
in the Dutch population.
Slattery et al. (31) have evaluated the association between
several genetic alterations and the presence or absence of
family history of colorectal cancer using incident colon
cancer cases. These authors did not find an association with
overall K-ras mutations, although patients with a G>T trans-
version of the second base of codon 12 were more likely
to have a family history of colorectal cancer compared with
those without this specific type of point mutation. In our study,
no significant differences were observed in family history
of CRC between patients without and with a K-ras muta-
tion. Our findings suggest that these genetic alterations
in sporadic colorectal tumours are not associated with
family history of CRC and that therefore, diet, environment
and/or lifestyle factors may contribute to the acquirement
of K-ras gene mutations involved in the early phases
of carcinogenesis. However, more studies evaluating
other genetic markers and/or a different kind of popula-
tion study, i.e. twin studies, may be necessary to address this
issue.
Studies from various countries have analysed the frequency
of the type of K-ras point mutation in colorectal cancer.
These studies were conducted in the UK (24,25), former
Yugoslavia (12), Czech Republic (21), Norway (9), Switzerland
(18), Mexico (11), USA (26) and The Netherlands (17,19,20).
All studies except for the study performed in former Yugosla-
via (12) have identified the G>A transition as the most fre-
quently found type of K-ras mutation. In the current study, the
G>A transition appeared also to be the predominant mutation.
The pattern of specific alterations observed, i.e. G>A transi-
tions and G>T transversions, could be due to differences in
diet and/or other lifestyle factors. N-nitroso compounds, for
example, in red and processed meat could induce G>A transi-
tions (25) and this is supported by previous experimental
studies (32,33). Two mechanisms, which could explain the
G>A transition are the formation of guanine-adducts in the
DNA and the silencing of the O6-methylguanine DNA methyl-
transferase (MGMT). MGMT is a DNA repair protein that
removes adducts from the O6 position of guanine (34) in
DNA. Promotor hypermethylation of the MGMT gene, a phe-
nomenon often seen in colon cancer cells (28,35) and which
leads to silencing of the gene, results in conversions of
guanine-cytosine pairs to adenine±thymine pairs. Guanine-to-
thymine transversions, however, are more likely to be induced
by carcinogenic agents like the polycyclic aromatic hydro-
carbons found in smoked and barbecued meat (36), dietary
fats (37) and cigarette smoke (38).
In the present study, codons 12 and 13 were affected in 94%
of the tumours with a K-ras mutation in the exon 1 fragment,
and the majority of mutations would result in an amino acid
substitution of glycine by aspartic acid (57%) or by valine
(33%). Mutations in either of these codons could lead to an
activated Ras protein. Al-Mulla et al. (39) compared detailed
crystal structures of the K-ras protein with these two most
frequently observed mutations in codon 12, i.e. substitutions
of glycine by aspartic acid or valine. The tightly bound com-
plex of GTP in codon 12 glycine-to-valine mutant Ras protein
may generate a more stable signal as compared with the codon
12 glycine-to-aspartic acid mutant Ras protein or the codon 12
wild-type Ras protein. Moreover, Andreyev et al. (27) have
shown that the presence of the glycine to valine substitution in
codon 12 leads to a decreased survival of CRC patients and
suggest this alteration is important for cancer progression and
also that it may predispose to a more aggressive biological
behaviour in patients with advanced colorectal cancer. Span
et al. (19) also observed an association between specific K-ras
point mutations and cancer progression. Recently, Bazan et al.
(40) reported biological relevance for codon 13 mutations in
terms of colorectal cancer clinical outcome, such as Dukes'
stage (P < 0.05). They also reported a possible role for codon
12 mutations in the mucinous differentiation pathway. Asso-
ciations between specific K-ras point mutations and cancer
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progression were, however, not supported by our and other
studies (3,26,41).
Eighteen patients were observed with an affected codon other
than codons 12 or 13. It is unknown whether mutations in these
codons lead to a constituent activation of the Ras protein. Our
results show that mutations in codons other than codons 12 or
13 of exon 1 are rare. The observed pattern of mutated codons,
i.e. 94% of the mutations were found in codons 12 and 13, is
probably due to a selective growth advantage (42).
Previous studies have presented frequencies of K-ras muta-
tions based on tissue samples of selected series of patients with
various distributions of Dukes' staged tumours. Some sug-
gested an increase in the frequencies of the K-ras oncogene
mutations with more advanced stages of Dukes' classification
(12,17) whereas others (3,9,42) did not find any association
between frequencies of point mutations and Dukes' stage. In
the current study, all incident CRC cases were included regard-
less of the Dukes' stage. No significant differences in the
distribution of Dukes' stage were observed between patients
without a K-ras mutation and those with a specific K-ras gene
mutation. It suggests that K-ras mutations are not involved in
the progression of adenocarcinomas and that genetic aberra-
tions occur in pathways, which do not depend on K-ras muta-
tions during the more advanced stages of colorectal cancer.
Various topographical subdivisions of the large intestine
have been proposed, according to different criteria (22,43±
45). The so-called rectosigmoid can be considered as a rather
more clinically applied term than an anatomically defined
transitional zone between the colon and rectum. Although the
rectum is considered to comprise the last 12 cm of the intestine
proximal of the anal verge, clinicopathological data are incon-
sistent as to whether the tumours in this region can be assigned
to the colon or rectum (46). In our study, the NCR database
contains the clinicopathological data, including the sub-
localization of the tumour, as supplied by the clinicians.
Therefore, in the current multi-centre study, for so-called
rectosigmoid tumours it was not possible to definitively assign
a tumour to either the colon or rectum. Consequently, the
rectosigmoid was excluded from analysis when comparing
colonic versus rectal adenocarcinomas. Among similar lines,
another topographical issue, which we addressed, was the
comparison of proximal versus distal colon tumours. Differ-
ences could be expected between these two with respect to
faecal content and composition, microbial flora and activity,
and the local variations in distribution of intestinal epithelial
cell types. Owing to the mentioned unclear definition of the
term rectosigmoid tumour, analyses were performed with both
the ex- and inclusion of rectosigmoid tumours within the group
of distal colon tumours. The resulting asymmetry between
proximal and distal colon tumours was maintained, regardless
of these differences in type of analysis.
Patients with a rectal tumour have a relatively higher fre-
quency of G>T transversions as compared with patients with
a distal colon tumour and this difference appeared to be most
pronounced for female patients. This was not found in other
studies (3,21,26,44). However, Breivik et al. (9) reported that
K-ras mutations were not found in tumours located proximal to
the descending colon of men under the age of 70, whereas rare
mutations such as G>C transversions were almost exclusively
observed in tumours of the rectum of women. Again, results
based on a smaller number of samples (123 men and 125
women, stratified by age) could lead to biased, inconsistent
associations. In the current study, G>C transversions also
constitute a small group of specific point mutations, but were
mainly observed in men with tumours in the distal colon and in
women with tumours in the proximal colon. Plausible explana-
tions for differences in tumour site could be the role of diet
with respect to bowel transit time and bacterial fermentation of
carbohydrates (47), production of volatile fatty acids (9) or
exposure of colonic epithelium to potential dietary carcino-
gens (48). The relatively high frequency of G>T transversions
in the rectum of women might be related to gender differences
in faecal concentration and transit time. Both bowel transit
time and frequency of constipation have been reported to be
substantially higher in women than in men under similar con-
ditions (49). The G>T transversions and also the generally
higher frequency of K-ras mutations in women might be
related to the time of contact with, and the concentration of,
particular carcinogens. More aetiological insight in the under-
lying mechanisms is required to clarify this issue.
The K-ras mutational status was evaluated for differences
in frequencies with respect to tumour differentiation. Most
tumours were classified as `moderately' differentiated.
Generally, the distinction between good or moderately differ-
entiated tumours is often ambiguous. Therefore, the classi-
fication of tumour differentiation could be biased. Our
findings do not support a role of the K-ras oncogene in tumour
differentiation.
In conclusion, we observed a frequency of 37% for muta-
tions in exon 1 fragment of the K-ras oncogene, predominantly
in codons 12 and 13. The G>A transition and the G>T trans-
version are the most frequently observed mutations, with the
G>T transversion primarily confined to codon 12. Patients
with a rectal tumour have a relatively higher frequency of
G>T transversion as compared to patients with a left colon
tumour and this is confined to female patients. The pattern of
K-ras point mutations observed in the several sub-localizations
of the colorectal tract is suggestive for the involvement of
dietary factors.
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